Page 29 - 2022-33-中国全科医学

·4122· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

［6］XU J，HUANG C，FAN G，et al. Use of angiotensin-converting from an Italian cohort of 133 hypertensives［J］. Am J Hypertens，
enzyme inhibitors and angiotensin II receptor blockers in context of 2020，33（10）：944-948. DOI：10.1093/ajh/hpaa096.
COVID-19 outbreak：a retrospective analysis［J］. Front Med， ［19］FENG Z C，LI J，YAO S H，et al. The use of adjuvant therapy
2020，14（5）：601-612. DOI：10.1007/s11684-020-0800-y. in preventing progression to severe pneumonia in patients with
［7］MENG J，XIAO G H，ZHANG J J，et al. Renin-angiotensin system coronavirus disease 2019：a multicenter data analysis［J］.
inhibitors improve the clinical outcomes of COVID-19 patients with medRxiv，2020. DOI：10.1101/2020.04.08.20057539.
hypertension［J］. Emerg Microbes Infect，2020，9（1）：757- ［20］REYNOLDS H R，ADHIKARI S，PULGARIN C，et al. Renin-
760. DOI：10.1080/22221751.2020.1746200. angiotensin-aldosterone system inhibitors and risk of COVID-
［8］ZHOU X，ZHU J K，XU T. Clinical characteristics of coronavirus 19［J］. N Engl J Med，2020，382（25）：2441-2448. DOI：
disease 2019 （COVID-19） patients with hypertension on renin- 10.1056/NEJMoa2008975.
angiotensin system inhibitors［J］. Clin Exp Hypertens，2020，42（7）： ［21］HUANG Z Y，CAO J T，YAO Y M，et al. The effect of RAS
656-660. DOI：10.1080/10641963.2020.1764018. blockers on the clinical characteristics of COVID-19 patients with
［9］LI J Y，WANG X F，CHEN J，et al. Association of renin- hypertension［J］. Ann Transl Med，2020，8（7）：430. DOI：
angiotensin system inhibitors with severity or risk of death in 10.21037/atm.2020.03.229.
patients with hypertension hospitalized for coronavirus disease 2019 ［22］徐梦丹，姚玉婷，吴莹，等 . 血管紧张素转换酶抑制药 / 血管
（COVID-19） infection in Wuhan，China［J］. JAMA Cardiol， 紧张素受体阻滞药治疗与新型冠状病毒肺炎合并高血压患者预
2020，5（7）：825-830. DOI：10.1001/jamacardio.2020.1624. 后的相关性［J］. 中华高血压杂志，2021，29（2）：126-132.
［10］HU J H，ZHANG X L，ZHANG X，et al. COVID-19 patients DOI：10.16439/j.issn.1673-7245.2021.02.006.
with hypertension have more severity condition，and ACEI/ XU M D，YAO Y T，WU Y，et al. Association of angiotensin
ARB treatment have no influence on the clinical severity and converting enzyme inhibitors/angiotensin receptor blockers
outcome［J］. J Infect，2020，81（6）：979-997. DOI： treatment and prognosis of patients with cornavirus disease 2019 and
10.1016/j.jinf.2020.05.056. hypertension［J］. Chinese Journal of Hypertension，2021，29（2）：
［11］ZHANG P，ZHU L H，CAI J J，et al. Association of inpatient 126-132. DOI：10.16439/j.issn.1673-7245.2021.02.006.
use of angiotensin-converting enzyme inhibitors and angiotensin Ⅱ ［23］GUAN W J，NI Z Y，HU Y，et al. China medical treatment expert
receptor blockers with mortality among patients with hypertension group for，Clinical Characteristics of Coronavirus Disease 2019
hospitalized with COVID-19［J］. Circ Res，2020，126（12）： in China［J］. N Engl J Med，2020，382（18）：1708-1720.
1671-1681. DOI：10.1161/CIRCRESAHA.120.317134. DOI：10.1056/NEJMoa2002032.
［12］SENKAL N，MERAL R，MEDETALIBEYOGLU A，et al. ［24］KREUTZ R，ALGHARABLY E A E，AZIZI M，et al.
Association between chronic ACE inhibitor exposure and decreased Hypertension，the renin-angiotensin system，and the risk of lower
odds of severe disease in patients with COVID-19［J］. Anatol J respiratory tract infections and lung injury：implications for COVID-
Cardiol，2020，24（1）：21-29. DOI：10.14744/AnatolJCardi 19［J］. Cardiovasc Res，2020，116（10）：1688-1699. DOI：
ol.2020.57431. 10.1093/cvr/cvaa097.
［13］SARDU C，MAGGI P，MESSINA V，et al. Could anti- ［25］KOCHI A N，TAGLIARI A P，FORLEO G B，et al. Cardiac
hypertensive drug therapy affect the clinical prognosis of hypertensive and arrhythmic complications in patients with COVID-19［J］. J
patients with COVID-19 infection? Data from centers of southern Cardiovasc Electrophysiol，2020，31（5）：1003-1008. DOI：
Italy［J］. J Am Heart Assoc，2020，9（17）：e016948. DOI： 10.1111/jce.14479.
10.1161/JAHA.120.016948. ［26］LI X C，ZHANG J F，ZHUO J L. The vasoprotective axes of
［14］YANG G，TAN Z H，ZHOU L，et al. Effects of angiotensin II the renin-angiotensin system：physiological relevance and
receptor blockers and ACE （angiotensin-converting enzyme） therapeutic implications in cardiovascular，hypertensive and kidney
inhibitors on virus infection，inflammatory status，and clinical diseases［J］. Pharmacol Res，2017，125（Pt A）：21-38.
outcomes in patients with COVID-19 and hypertension：a single- DOI：10.1016/j.phrs.2017.06.005.
center retrospective study［J］. Hypertension，2020，76（1）： ［27］PRANATA R，PERMANA H，HUANG I，et al. The use of renin
51-58. DOI：10.1161/HYPERTENSIONAHA.120.15143. angiotensin system inhibitor on mortality in patients with coronavirus
［15］XIAO G H，HU H B，WU F，et al. Acute kidney injury in patients disease 2019 （COVID-19）：a systematic review and meta-
hospitalized with COVID-19 in Wuhan，China：a single-center analysis［J］. Diabetes Metab Syndr，2020，14（5）：983-990.
retrospective observational study［J］. J South Med Univ，2021， DOI：10.1016/j.dsx.2020.06.047.
41（2）：157-163. DOI：10.12122/j.issn.1673-4254.2021.02.01. ［28］SON M，SEO J，YANG S. Association between renin-angiotensin-
［16］LIU Y X，XU J，YANG P H，et al. Anti-hypertensive angiotensin aldosterone system inhibitors and COVID-19 infection in south
Ⅱ receptor blockers associated to mitigation of disease severity Korea［J］. Hypertension，2020，76（3）：742-749. DOI：
in elderly COVID-19 patients［J］. medRxiv，2020. DOI： 10.1161/HYPERTENSIONAHA.120.15464.
10.1101/2020.03.20.20039586. ［29］CHEN N S，ZHOU M，DONG X，et al. Epidemiological and
［17］GAO C，CAI Y，ZHANG K，et al. Association of hypertension clinical characteristics of 99 cases of 2019 novel coronavirus
and antihypertensive treatment with COVID-19 mortality：a pneumonia in Wuhan，China：a descriptive study［J］. Lancet，
retrospective observational study［J］. Eur Heart J，2020，41（22）： 2020，395（10223）：507-513. DOI：10.1016/S0140-
2058-2066. DOI：10.1093/eurheartj/ehaa433. 6736(20)30211-7.
［18］FELICE C，NARDIN C，DI TANNA G L，et al. Use of RAAS （收稿日期：2022-04-11；修回日期：2022-06-15）
inhibitors and risk of clinical deterioration in COVID-19：results （本文编辑：崔莎）